- Home
- IGIC vs GYRE Comparison
IGIC vs GYRE Comparison
Compare IGIC & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGIC
- GYRE
- Stock Information
- Founded
- IGIC 2001
- GYRE 2002
- Country
- IGIC Jordan
- GYRE United States
- Employees
- IGIC N/A
- GYRE N/A
- Industry
- IGIC Property-Casualty Insurers
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- IGIC Finance
- GYRE Health Care
- Exchange
- IGIC Nasdaq
- GYRE Nasdaq
- Market Cap
- IGIC 1.1B
- GYRE 1.3B
- IPO Year
- IGIC N/A
- GYRE N/A
- Fundamental
- Price
- IGIC $24.01
- GYRE $11.50
- Analyst Decision
- IGIC Buy
- GYRE
- Analyst Count
- IGIC 3
- GYRE 0
- Target Price
- IGIC $23.67
- GYRE N/A
- AVG Volume (30 Days)
- IGIC 119.6K
- GYRE 126.3K
- Earning Date
- IGIC 11-05-2024
- GYRE 11-13-2024
- Dividend Yield
- IGIC 2.40%
- GYRE N/A
- EPS Growth
- IGIC 32.83
- GYRE N/A
- EPS
- IGIC 3.04
- GYRE N/A
- Revenue
- IGIC $506,160,000.00
- GYRE $105,033,000.00
- Revenue This Year
- IGIC N/A
- GYRE $25.32
- Revenue Next Year
- IGIC $6.64
- GYRE $12.95
- P/E Ratio
- IGIC $7.91
- GYRE N/A
- Revenue Growth
- IGIC 10.67
- GYRE N/A
- 52 Week Low
- IGIC $11.51
- GYRE $8.26
- 52 Week High
- IGIC $27.00
- GYRE $30.40
- Technical
- Relative Strength Index (RSI)
- IGIC 46.72
- GYRE 54.43
- Support Level
- IGIC $23.60
- GYRE $9.61
- Resistance Level
- IGIC $24.72
- GYRE $12.58
- Average True Range (ATR)
- IGIC 0.73
- GYRE 1.12
- MACD
- IGIC -0.37
- GYRE 0.16
- Stochastic Oscillator
- IGIC 15.83
- GYRE 79.51
About IGIC International General Insurance Holdings Ltd.
International General Insurance Holdings Ltd is an international specialist commercial insurer and a reinsurer, underwriting a diverse portfolio of specialty lines. The company operates in a portfolio of Energy, Property, Construction, Engineering, Ports and terminals, Financial Institutions, General Aviation, Professional Indemnity, Casualty, Directors and Officers, Political Violence, Forestry, and Treaty Reinsurance. Its operating segment includes Specialty Longtail; Specialty Short tail and Reinsurance.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.